Sarah Cannon Research Institute and Merck Collaborate to Expand Access to Oncology Clinical TrialsBusiness Wire • 08/13/26
Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequencesCNBC • 08/11/26
MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?Zacks Investment Research • 08/11/26
Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?Zacks Investment Research • 08/06/26
U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second SeasonBusiness Wire • 08/06/26
Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/04/26
Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal chargesCNBC • 08/04/26
The Merck Product That Absolutely Demolished Wall Street's ForecastsInvestors Business Daily • 08/04/26
Merck Delivers a Clean Earnings Beat on Oncology Strength. Is It Enough to Impress Wall Street?Barrons • 08/04/26
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse PipelineBusiness Wire • 08/04/26
Merck & Co., Inc. (MRK) Discusses HIV Program Updates and Phase III Data from International AIDS Conference TranscriptSeeking Alpha • 08/03/26
Merck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less SteepSeeking Alpha • 07/31/26